Overview

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

Status:
RECRUITING
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of KarXT for the treatment of manic episodes in Bipolar-I Disorder
Phase:
PHASE3
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
trospium chloride
xanomeline